

LEQVIO (INCLISIRAN) INJECTION ORDERS

A Carelon Company	1		P: 8//	.365.5566 1:85	5.889.2946
PATIENT INFORMATIO	N: Fax comple	eted form, insurar	nce informati	on, and clinical documentati	on to 855.889.2946
Patient Name:				Phone:	
Patient Status: New to The second	nerapy 🗆 Continui	ng Therapy	Next Trea	tment Date:	
MEDICAL INFORMATIO	N				
Diagnosis:					
D Pure hypercholesterolemia	a, unspecified (ICD	-10: E78.00)			
□ Familial hypercholesterole	emia (ICD-10: E78.0)1)			
☐ Mixed hyperlipidemia (ICD)-10: E78.2)				
Hyperlipidemia, unspecifie	ed (ICD-10: E78.5)				
□ ASCHD w/o angina pecto	ris (ICD-10: I25.10)				
Other:		_ ICD-10:			
Patient Weight: lbs. ((required) Allergie	es:			

THERAPY ORDER

Leqvio - choose one:

284mg subcutaneously initially, at 3 months, and then every 6 months (initial start) x 1 year

□ 284mg subcutaneously every 6 months x 1 year

Lab Orders:		Lab Frequency:
Required labs to be drawn by:	🗌 Paragon	Referring Provider

Other orders:

PROVIDER INFORMATION

	lizing our services, you are authorizing <i>Paragon Health</i> al and prescription insurance companies, and to select			and specialty pharmacy designated					
Provider Name: _	vider Name: Signature:								
	Phone:								
□ Opt out of Paragon selecting site of care (if checked, please list site of care):									
PREFERRED I	LOCATION								
City:	State:	_ View our lo	ocations here:						
	PARA ax is intended to be delivered only to the named add								

istribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





A Carelon Company

PATIENT INFORMATION:

Patient Name:

DOB:

REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

- □ Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)
- □ Include patient demographic information and insurance information
- □ Include patient's current medication list
- □ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
 - □ Heterozygous familial hypercholesterolemia (HeFH) Does the patient have a untreated LDL ≥ 190mg/dL (≥ 155mg/dL if <16 years of age)? □ Yes □ No
 - <u>Please mark any of the following criteria the HeFH patient meets:</u>
 - \Box Presence of tendon xanthoma(s) in the patient or 1st/2nd degree relative
 - □ Family history of MI at <60 years old in 1st degree relative or <50 years old in 2nd degree relative
 - □ Family history of total cholesterol > than 290mg/dL in a 1st/2nd degree relative
 - □ Arcus cornealis before age 45
 - □ ASCVD Does the patient's LDL remain ≥ 100mg/dL despite treatment with a highintensity statin? □ Yes □ No
 - □ Has the patient tried and failed PCSK9 inhibitor after 12 weeks of use? □ Yes □ No
 - \Box Has the patient tried and failed a high intensity statin for \geq 8 continuous weeks? \Box Yes \Box No
 - □ Indicate any conditions the patient has:
 - □ Acute coronary syndrome □ History of myocardial infarction □ Stroke
 - Coronary or other arterial revascularization Transient ischemic attack
 - Peripheral arterial disease presumed to be of atherosclerotic origin

□ Include labs and/or test results to support diagnosis

- LDL-C (required)
- □ Mutation in LDL, apoB, or PCSK9 gene (if applicable)

Other medical necessity: _____

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.